Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024.
- First-quarter revenue was $1.62 billion, which is up 5% on a reported basis and 7% at constant currency
- Women’s Health revenue increased by 11% and Biosimilars revenue climbed by 46%
- Meanwhile, Established Brands revenue was flat on an as-reported basis during the quarter
- Reported earnings per share and adjusted earnings per share were $0.78 and $1.22, respectively, during the three months
- Net income came in at $201 million in the March quarter and adjusted EBITDA was $538 million
- Gross margin was 59.0% on a reported basis and 62.1% on an adjusted basis in the first quarter
- Adjusted EBITDA margin dropped to 33.2% in the first quarter from 33.7% last year
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Accenture (ACN) to report Q2 2025 results Thursday. Here’s what to expect
Accenture plc, (NYSE: ACN) is preparing to publish its second-quarter results this week, amid expectations for a year-over-year increase in revenue and profit. The professional services company had a strong
What to expect when Dollar Tree (DLTR) reports Q4 2024 earnings results
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) gained over 1% on Monday. The stock has dropped 6% over the past three months. The discount store chain is scheduled to report
MU Earnings Preview: Strong Q2 results in cards amid growing AI demand
Micron Technology, Inc. (NASDAQ: MU) is uniquely positioned to capitalize on the AI wave sweeping the tech industry, leveraging its high-bandwidth-memory products designed for massive data processing tasks. The company
